Relation of the rs6923761 gene variant in glucagon-like peptide 1 receptor to metabolic syndrome in obese subjects.
The role of glucagon-like peptide 1 (GLP-1) variants in metabolic syndrome (MS) and its components remains unclear in obese subjects. The aim of our study was to evaluate the relationship of rs6923761 with MS and its components in obese subjects. A population of 1,122 obese subjects was analyzed in a cross-sectional survey. To estimate the prevalence of MS, we considered the definitions of the Adult Treatment Panel III. Five hundred and forty-eight patients (48.8%) had the GG genotype (wild-type group), whereas 487 patients (43.4%) had the GA genotype and 87 patients (7.8%) the AA genotype. The mean age was 48.9 ± 12.8 years. The prevalence of MS was 47.4% (532 patients), and 52.6% of patients had no MS (n = 590). The odds ratio of MS for the wild-type versus the mutant genotype was 1.02, with a 95% confidence interval of 0.88-1.12. Body mass index, weight, fat mass, waist circumference, and waist to hip ratio were lower in the mutant than in the wild-type group in patients with and without MS. The GLP-1 receptor variant rs6923761 was found to be associated with decreased weight and anthropometric parameters in A allele carriers with and without MS. MS or its components were not associated with this polymorphism in obese adults.